Shah Pritesh 4
4 · NovoCure Ltd · Filed Mar 11, 2022
Insider Transaction Report
Form 4
NovoCure LtdNVCR
Shah Pritesh
Chief Commercial Officer
Transactions
- Sale
Ordinary Shares
2022-03-09$71.19/sh−3,669$261,196→ 83,187 total - Exercise/Conversion
Restricted Stock Units
2021-07-31−3,717→ 3,717 totalExercise: $0.00From: 2021-07-31→ Ordinary Shares (3,717 underlying) - Exercise/Conversion
Ordinary Shares
2021-07-31$154.01/sh+3,717$572,455→ 85,625 total
Footnotes (3)
- [F1]Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah.
- [F2]Amended total to correct prior mathematical error.
- [F3]Fully vested as of the date hereof.